Modulation of chondrocyte production of extracellular inorganic pyrophosphate

Current Opinion in Rheumatology

Volumn 16, Issue 3, 2004, Pages 268-272

  Costello, Jill C ^a   Ryan, Lawrence M ^b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b NONE

Author keywords

ANK; BCP; CPPD; Nucleoside triphosphate pyrophosphohydrolase (NTPPPH); Transglutaminase

Indexed keywords

ALKALINE PHOSPHATASE; BLOOD CLOTTING FACTOR 13A; CHEMOKINE; ENZYME; INTERLEUKIN 1BETA; NUCLEOSIDE TRIPHOSPHATE PYROPHOSPHATASE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; PYROPHOSPHATE; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG;

ANK GENE; ANKYLOSING SPONDYLITIS; ARTICULAR CARTILAGE; BONE DISEASE; BONE MINERALIZATION; CARTILAGE CELL; CELL MEMBRANE; CLINICAL FEATURE; CRANIOMETAPHYSEAL DYSPLASIA; ENZYME ACTIVITY; GENE; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; KNOCKOUT MOUSE; MEMBRANE TRANSPORT; NONHUMAN; OSTEOARTHRITIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

CALCIUM PHOSPHATES; CALCIUM PYROPHOSPHATE; CARTILAGE, ARTICULAR; CHONDROCALCINOSIS; CHONDROCYTES; CRYSTALLIZATION; DIPHOSPHATES; EXTRACELLULAR SPACE; HUMANS; PHOSPHORIC DIESTER HYDROLASES; PYROPHOSPHATASES; SYNOVIAL FLUID; TRANSGLUTAMINASES;

EID: 1942531958     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200405000-00017     Document Type: Review

References (24)

1. Ho AM, Johnson MD, Kingsley DM: Role of the mouse ank gene in control of tissue calcification and arthritis. Science 2000, 289:265-270.
2. Johnson K, Goding J, Van Etten D, et al.: Linked deficiencies in extracellular PPi and osteopontin mediate pathologic calcification associated with defective PC-1 and ANK expression. J Bone Miner Res 2003, 18:994-1004. This article offers insight into the interplay among modulators of pathologic calcification.
3. Nurnberg P, Thiele H, Chandler D, et al.: Heterozygous mutations in ANKH, the human ortholog of the mouse progressive ankylosis gene, result in craniometaphyseal dysplasia. Nat Genet 2001, 28:37-41.
4. Reichenberger E, Tiziani V, Watanabe S, et al.: Autosomal dominant craniometaphyseal dysplasia is caused by mutations in the transmembrane protein ANK. Am J Hum Genet 2001, 68:1321-1326.
5. Tsui FWL, Tsui HW, Cheng EY, et al.: Novel genetic markers in the 5′-flanking region of ANKH are associated with ankylosing spondylitis. Arthritis Rheum 2003, 48:791-797.
6. Timms AE, Zhang Y, Bradbury L, et al.: Investigation of the role of ANKH in ankylosing spondylitis. Arthritis Rheum 2003, 48:2898-2902.
7. Hughes AE, McGibbon D, Woodward E, et al.: Localization of a gene for chondrocalcinosis to chromosome 5p. Hum Mol Genet 1995, 4:1225-1228.
8. Andrew LJ, Brancolini L, de la Pena S, et al.: Refinement of the chromosome 5p locus for familial calcium pyrophosphate dihydrate deposition disease. Am J Hum Genet 1999, 64:136-145.
9. Williams CJ, Pendleton A, Bonavita G, et al.: Mutations in the amino terminus of ANKH in two US families with calcium pyrophosphate dihydrate crystal deposition disease. Arthritis Rheum 2003, 48:2627-2631.
10. Hirose J, Ryan L, Masuda I: Up-regulated expression of cartilage intermediate-layer protein and ANK in articular cartilage from patients with calcium pyrophosphate dihydrate crystal deposition disease. Arthritis Rheum 2002, 46:3218-3229. This paper notes the correlation of ANK and CILP expression in cartilage with crystal deposition.
11. Hessle L, Johnson KA, Anderson CA, et al.: Tissue-nonspecific alkaline phosphatase and plasma cell membrane glycoprotein-1 are central antagonistic regulators of bone mineralization. Proc Nat Acad Sci U S A 2002, 99:9445-9449.
12. Rutsch F, Vaingankar S, Johnson K, et al.: PC-1 nucleoside triphosphate pyrophosphohydrolase deficiency in idiopathic infantile arterial calcification. Am J Pathol 2001, 158:543-554.
13. Rutsch F, Ruf N, Vaingankar S, et al.: Mutations in ENPP1 are associated with "idiopathic" infantile arterial calcification. Nat Genet 2003, 34:379-381. This article presents a genetic definition of this heretofore idiopathic condition.
14. Lorenzo P, Bayliss MT, Heinegard D: A novel cartilage protein (CILP) present in the mid-zone of human articular cartilage increases with age. J Biol Chem 1998, 273:23463-23468.
15. 14a Masuda I, Hamada J, Haas AL, et al.: A unique ectonucleotide pyrophohydrolase associated with porcine chondrocyte-derived vesicles. J Clin Invest 1995, 95:699-704.
16. Johnson K, Farley D, Hu S-I, et al.: One of two chondrocyte-expressed isoforms of cartilage intermediate-layer protein functions as an insulin-like growth factor 1 antagonist. Arthritis Rheum 2003, 48:1302-1314. This paper defines a functional role for CILP.
17. Yamakawa K, Iwasaki H, Masuda I, et al.: Cartilage intermediate layer protein expression in calcium pyrophosphate dihydrate crystal deposition disease. J Rheumatol 2002, 29:1746-1753.
18. Rosenthal AK, Gohr CM, Henry LA, et al.: Participation of transglutaminase in the activation of latent transforming growth factor beta 1 in aging articular cartilage. Arthritis Rheum 2000, 43:1729-1733.
19. Rosenthal AK, Masuda I, Gohr CM, et al.: The transglutaminase, factor XIIIA, is present in articular chondrocytes. Osteoarthritis Cartilage 2001, 9:578-581.
20. Wilhelm B, Meinhardt A, Seitz J: Transglutaminases: purification and activity assays. J Chromatogr 1996, 864:163-177.
21. Johnson K, Hashimoto S, Lotz M, et al.: Interleukin-1 induces pro-mineralizing activity of cartilage tissue transglutaminase and factor XIIIa. Am J Pathol 2001, 159:149-163.
22. Johnson KA, Van Etten D, Nanda N, et al.: Distinct transglutaminase 2-independent and transglutaminase 2-dependent pathways mediate articular chondrocyte hypertrophy. J Biol Chem 2003, 278:18824-18832.
23. Merz R, Uu R, Johnson K, et al.: IL-8/CXCL8 and growth-regulated oncogene α/CXCL1 induce chondrocyte hypertrophic differentiation. J Immunol 2003, 171:4406-4415.
24. Rosenthal AK, Heinkel D, Gohr CM: Thyroxine stimulates transglutaminase activity in articular chondrocytes. Osteoarthritis Cartilage 2003, 11:463-470.